RESUMO
This study was designed to evaluate the effect of topical levobunolol 0.5% [non selective beta blocker] on plasma lipid levels. Fifteen glaucomatous patients not using any medications known to alter the plasma lipid levels, non diabetic or obese were selected. These patients used topical levobunolol 0.5% in both eyes twice daily for treatment of glaucoma for three months, they were subjected to measurements of their IOP. C/D ratio, heart rate, blood pressure, body weight and fasting plasma lipid levels before treatment and monthly for three months. We found that, topical levobunolol 0.5% is effective in controlling IOP but on the other hand there was a 50% increase in triglycerides. 20% decrease in high density lipoprotein, 15% increase in total lipids while there were no significant changes in total cholesterol and low density lipoprotein. These changes are known to increase the risk of coronary heart disease and shift the patients to the high risk category